Christian Behrenbruch

ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA.

Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA.

Amplia Therapeutics Pty Ltd. manufactures pharmaceutical products. The company was founded by Chris Behrenbruch and is headquartered in Australia.

Advanced Nuclear Medicine Ingredients SA engages in the distribution of pharmaceutical ingredients. Its products and services include toward cold kits for PET, custom peptide synthesis, new theranostic cold kits and theranostic development. The company was founded by Bruno Colard, Severine Plunus, Laurent Bodson, Monique Body, Amadeo Falcone, Sabine Lurson, Gael Minon, Michel Falcone, Vanessa Charlier, Chantal Riviere, Jean Francois Kaisin, Samuel Voccia, and Ludovic Wouters on March 27, 2015 and is headquartered in Liege, Belgium.